As factor XIII
has a long half-life, prophylactic replacement therapy every 4 weeks with factor XIII
concentrate or cryoprecipitate is effective as a preventive strategy.
Role of factor XIII
in fibrin clot formation and effects of genetic polymorphisms.
The discovery of coagulation factor XIII
(FXIII) dates back to 1940s when a "serum factor" was found to make the fibrin clot insoluble in concentrated urea solution.
Keywords: Factor XIII
deficiency, Bleeding disorder, Ovarian haemorrhage, Splenic haematoma.
influences fibrinolysis by the cross-linking fibrin [alpha] chains into high-molecular-weight polymers, rendering the clot more resistant to lysis.
Valproate induces reversible factor XIII
deficiency with risk of perioperative bleeding.
Other polymorphic sites related to FXIII activity are FXIII 614A/T and FXIII 1694C/T polymorphisms which have been associated with decreased plasma factor XIII
concentrations and lower activity rates, making these FXIII variants candidates for the pathogenesis of thrombotic disorders (8, 10-12).
1), (2) Los sellantes de fibrina pertenecen al grupo de productos con propiedades adhesivas y hemostaticas derivados principalmente del plasma humano, contienen fibrinogeno, trombina, factor XIII
, fibronectina, aprotinina y cloruro de calcio.
Clot solubility test was performed to screen factor XIII
18 February 2011 - The US Food and Drug Administration (FDA) approved yesterday Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII
Now, a new analysis of the cement reveals that it has many of the same properties as a human blood coagulant, factor XIII
, which helps to form scabs.
ROTEM measures the formation, stabilisation and eventual lysis of the clot, including platelet function and fibrin polymerisation (including factor XIII
activity), important parameters that are not detected in standard clotting assays.
La deficiencia de factor XIII
de la coagulacion hace parte del grupo de los trastornos raros de la hemostasia, entre los cuales se hallan aquellos distintos a los de los factores VIII y IX: factores I, II, V, V+VIII, VII, X y XI.
Significant independent risk factors for chronic renal disease in these patients were severe abdominal symptoms, prolonged purpura, and decreased factor XIII
Drugs (see Table 4) Wiskott-Aldrich syndrome, May-Hegglin anomaly Systemic illness (liver disease, myeloproliferative disorder, infection) Platelet dysfunction Drugs Myeloproliferative disorder Von Willebrand disease Thrombocytopenia Absent Radius (TAR) syndrome Bernard-Soulier Glanzmann thrombasthenia Storage disease Renal disease Coagulation protein disorders Hemophilia (factor VIII, IX, XI deficiency) Von Willebrand disease Dysfibrinogenemia Factor XIII
Plasmin or plasminogen deficiency or inhibitor Circulating anticoagulant or inhibitor Vitamin K deficiency, warfarin therapy Systemic illnesses (liver disease, amyloidosis) Table 2.